

The European Patent Office has invalidated the LMA patent that is the foundation for the lawsuits against Ambu in Europe

The European Patent Office in Munich has ruled the European patent (EP 111 9 386) invalid, which LMA has maintained in connection with the pending lawsuits in Germany, The Netherlands and France regarding Ambu's laryngeal mask.

The ruling by the European Patent Office can be appealed.

Ambu is satisfied with the ruling

Background

Ambu has since autumn 2005 been involved in a lawsuit about alleged patent infringement.

Thus in the autumn of 2005, legal proceedings were instituted against Ambu by the company LMA before a German court with a claim being set up that Ambu with its laryngeal mask had infringed LMA' patent on the reinforcement of the tip of the laryngeal mask.

During the entire proceedings, Ambu has claimed that there was in fact no infringement of LMA' patent, and at the beginning of 2006, Ambu filed an objection against the validity of LMA's patent to the European Patent Office in Munich.

Contact: K.E. Birk, tel. +45 7225 2000, email keb@ambu.com

Ambu develops, produces and markets diagnostic and life-supporting devices to hospitals and rescue services. Ambu has five business areas: Respiratory Care, Cardiology, Neurology, Training and Immobilization. The most important business areas are Respiratory Care, Cardiology and Neurology, and the most important products in these areas are ventilation products for artificial respiration and single-use electrodes for ECG recordings and neurophysiological examinations. Ambu's products are sold worldwide. Exports account for 98% of sales, and sales are handled via Ambu's foreign subsidiaries or via distributors. Ambu has just over 1,200 employees, of whom approx. 300 work in Denmark and approx. 900 abroad.

Ambu A/S
Baltorpbakken 13 T + 45 72 25 20 00
DK-2750 Ballerup F + 45 72 25 20 50
CVR: 63 64 49 19 www.ambu.com

